Difference between revisions of "Transformation of PGJ2 to 15-D-PGJ2"
Line 12: | Line 12: | ||
== Rate equation == | == Rate equation == | ||
+ | [[File:R09.PNG|center|500px]] | ||
== Parameters == | == Parameters == | ||
− | + | * [[Transformation of PGD2 to PGJ2 |See transformation of PGD2 to PGJ2]] | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
== Related Reactions == | == Related Reactions == | ||
* [[Transformation of PGD2 to PGJ2 |Transformation of PGD2 to PGJ2]] | * [[Transformation of PGD2 to PGJ2 |Transformation of PGD2 to PGJ2]] |
Revision as of 15:29, 25 September 2017
Due to the lack of PGD2 production by keratinocyte and fibroblast cells, the anti-inflammatory cyclopentanones, PGJ2 and 15d-PGJ2, will not be produced during early experimental procedures either.